Comparative Pharmacology
Head-to-head clinical analysis: LITHANE versus LITHOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LITHANE versus LITHOBID.
LITHANE vs LITHOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lithium is thought to modulate neurotransmitter release and second messenger systems, including inhibition of inositol monophosphatase and alterations in G-protein signaling, though exact mechanism in bipolar disorder is unclear.
Lithium modulates neurotransmitter receptors and second messenger systems; inhibits inositol monophosphatase, reducing phosphoinositide signaling; alters ion transport; enhances serotonin and norepinephrine reuptake; modulates G-proteins.
300-600 mg orally 3 times daily; usual therapeutic serum lithium level 0.6-1.2 mEq/L. Extended-release formulations given 2-3 times daily.
300-600 mg orally 2-3 times daily; extended-release formulation (LITHOBID) 300-450 mg orally twice daily.
None Documented
None Documented
18-24 hours (single dose); 24-36 hours after chronic dosing; prolonged in elderly or renal impairment.
Terminal elimination half-life: 18-36 hours (mean 24 hours) in young adults, increases with age and renal impairment. Long half-life supports once-daily dosing in sustained-release formulation.
Renal: >95% unchanged; tubular reabsorption parallels sodium; negligible biliary/fecal.
Renal: >95% excreted unchanged in urine. Biliary/fecal: <5%.
Category C
Category C
Mood Stabilizer
Mood Stabilizer